PortfoliosLab logoPortfoliosLab logo
NVO vs. AJG
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVO vs. AJG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novo Nordisk A/S (NVO) and Arthur J. Gallagher & Co. (AJG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVO achieves a 0.91% return, which is significantly higher than AJG's -1.36% return. Over the past 10 years, NVO has underperformed AJG with an annualized return of 8.18%, while AJG has yielded a comparatively higher 19.74% annualized return.


NVO

1D
-1.41%
1M
14.86%
6M
-17.63%
YTD
0.91%
1Y
-19.26%
3Y*
-13.51%
5Y*
4.43%
10Y*
8.18%
ALL TIME*
14.52%

AJG

1D
-0.09%
1M
18.50%
6M
-1.25%
YTD
-1.36%
1Y
-18.08%
3Y*
6.09%
5Y*
13.67%
10Y*
19.74%
ALL TIME*
12.61%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NVO vs. AJG - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NVO
Novo Nordisk A/S
0.91%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%
AJG
Arthur J. Gallagher & Co.
-1.36%-8.03%27.34%20.51%12.44%39.02%32.12%31.79%19.19%25.04%

Correlation

The correlation between NVO and AJG is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.14

Correlation (3Y)
Calculated over the trailing 3-year period

0.17

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Sep 7, 1984

0.17

Fundamentals

Market Cap

NVO:

$220.46B

AJG:

$65.18B

EPS

NVO:

DKK 27.42

AJG:

$5.74

PE Ratio

NVO:

11.83

AJG:

44.21

PEG Ratio

NVO:

0.51

AJG:

4.58

PS Ratio

NVO:

4.40

AJG:

4.74

Total Revenue (TTM)

NVO:

DKK 327.80B

AJG:

$13.94B

Gross Profit (TTM)

NVO:

DKK 268.30B

AJG:

$7.63B

EBITDA (TTM)

NVO:

DKK 181.54B

AJG:

$3.66B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVO vs. AJG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVO
NVO Risk / Return Rank: 3030
Overall Rank
NVO Sharpe Ratio Rank: 2929
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 2929
Sortino Ratio Rank
NVO Omega Ratio Rank: 2929
Omega Ratio Rank
NVO Calmar Ratio Rank: 3232
Calmar Ratio Rank
NVO Martin Ratio Rank: 3333
Martin Ratio Rank

AJG
AJG Risk / Return Rank: 2323
Overall Rank
AJG Sharpe Ratio Rank: 1717
Sharpe Ratio Rank
AJG Sortino Ratio Rank: 1919
Sortino Ratio Rank
AJG Omega Ratio Rank: 1919
Omega Ratio Rank
AJG Calmar Ratio Rank: 2929
Calmar Ratio Rank
AJG Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVO vs. AJG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Arthur J. Gallagher & Co. (AJG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NVOAJGDifference
Sharpe ratioReturn per unit of total volatility

+0.24

Sortino ratioReturn per unit of downside risk

+0.50

Omega ratioGain probability vs. loss probability

0.97

0.91

+0.06

Calmar ratioReturn relative to maximum drawdown

-0.39

-0.47

+0.08

Martin ratioReturn relative to average drawdown

-0.61

-0.79

+0.18

NVO vs. AJG - Sharpe Ratio Comparison

The current NVO Sharpe Ratio is -0.37, which is higher than the AJG Sharpe Ratio of -0.61. The chart below compares the historical Sharpe Ratios of NVO and AJG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NVO vs. AJG - Drawdown Comparison

The maximum NVO drawdown since its inception was -74.70%, which is greater than AJG's maximum drawdown of -57.49%. Use the drawdown chart below to compare losses from any high point for NVO and AJG.


Loading charts...

Drawdown Indicators


NVOAJGDifference

Max Drawdown

Largest peak-to-trough decline

-74.70%

-57.49%

-17.21%

Max Drawdown (1Y)

Largest decline over 1 year

-49.17%

-38.59%

-10.58%

Max Drawdown (3Y)

Largest decline over 3 years

-74.70%

-44.40%

-30.30%

Max Drawdown (5Y)

Largest decline over 5 years

-74.70%

-44.40%

-30.30%

Max Drawdown (10Y)

Largest decline over 10 years

-74.70%

-44.40%

-30.30%

Current Drawdown

Current decline from peak

-63.95%

-26.31%

-37.64%

Average Drawdown

Average peak-to-trough decline

-17.89%

-12.87%

-5.02%

Ulcer Index

Depth and duration of drawdowns from previous peaks

31.75%

23.05%

+8.70%

Volatility

NVO vs. AJG - Volatility Comparison

The current volatility for Novo Nordisk A/S (NVO) is 9.48%, while Arthur J. Gallagher & Co. (AJG) has a volatility of 10.92%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than AJG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVOAJGDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.48%

10.92%

-1.44%

Volatility (6M)

Calculated over the trailing 6-month period

37.43%

24.11%

+13.32%

Volatility (1Y)

Calculated over the trailing 1-year period

51.79%

29.72%

+22.07%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

38.58%

23.42%

+15.16%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

32.63%

23.24%

+9.39%

Dividends

NVO vs. AJG - Dividend Comparison

NVO's dividend yield for the trailing twelve months is around 3.63%, more than AJG's 1.06% yield.


PositionTTM20252024202320222021202020192018201720162015
AJG
Arthur J. Gallagher & Co.
1.06%1.00%0.85%0.98%1.08%1.13%1.46%1.81%2.23%2.47%2.93%3.62%
NVO
Novo Nordisk A/S
3.63%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%

Financials

NVO vs. AJG - Financials Comparison

This section allows you to compare key financial metrics between Novo Nordisk A/S and Arthur J. Gallagher & Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
96.82B
3.63B
(NVO) Total Revenue
(AJG) Total Revenue
Please note, different currencies. NVO values in DKK, AJG values in USD

NVO vs. AJG - Profitability Comparison

The chart below illustrates the profitability comparison between Novo Nordisk A/S and Arthur J. Gallagher & Co. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%90.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
86.0%
39.1%
Portfolio components
NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

AJG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Arthur J. Gallagher & Co. reported a gross profit of 1.42B and revenue of 3.63B. Therefore, the gross margin over that period was 39.1%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

AJG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Arthur J. Gallagher & Co. reported an operating income of 341.00M and revenue of 3.63B, resulting in an operating margin of 9.4%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.

AJG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Arthur J. Gallagher & Co. reported a net income of 151.00M and revenue of 3.63B, resulting in a net margin of 4.2%.


Frequently Asked Questions


NVO and AJG have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AJG has higher volatility (10.92%) compared to NVO (9.48%). In terms of maximum drawdown, NVO dropped -74.70% vs AJG's -57.49%.

NVO currently has the higher Sharpe Ratio (-0.37 vs -0.61), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVO and AJG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer